Return
Targeted Transcriptomic Profiling Identifies Biomarkers and Molecular Features Associated With Immunotherapy Response in Classic Hodgkin Lymphoma
L
M
L
K
L
L
I
H
L
F
DOI:10.1016/j.modpat.2026.101060.png)
Abstract
En 中文
Classic Hodgkin lymphoma (CHL) is a highly curable disease. However, a subset of patients develops relapsed/refractory disease, underscoring the need for predictors of treatment response. Although immune-checkpoint inhibitors have improved outcomes, many patients still experience suboptimal responses. A deeper understanding of the CHL transcriptomic landscape may improve patient stratification and guide treatment approaches.
Journal
IF:
5.5
Papers:
5.2K
Citations:
1.8W
